Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

New Saliva Test Accurately Detects HPV-Associated Head and Neck Cancer

TOP - November 2021 Vol 14, No 7 - Head and Neck Cancer

Oropharyngeal cancer, which can develop at the base of the tongue, tonsils, and the middle part of the throat, is primarily caused by human papillomavirus (HPV) infection, the most common sexually transmitted virus and infection in the United States.1 Over the past 2 decades, cases of HPV-positive oropharyngeal squamous-cell carcinoma (OPSCC) have been increasing at an alarming rate among men in the United States.2,3 According to the American Cancer Society, approximately 54,000 cases of oropharyngeal and oral cavity cancer will be diagnosed in the United States in 2021, and more than 10,000 individuals will die from the disease.4 OPSCC is often diagnosed at an advanced stage, resulting in increased mortality and morbidity.

During the American Society of Clinical Oncology 2021 virtual annual meeting, researchers from the Washington University School of Medicine, St. Louis, MO, discussed results from a study using a clinically validated saliva test to accurately detect HPV-associated head and neck cancer. The assay used in the study (NavDx) analyzes saliva for sequences of the HPV genome that are specific for HPV DNA released from malignant tumors. It distinguishes tumor-tissue modified viral HPV (TTMV-HPV) from noncancerous sources of HPV DNA and measures the number of TTMV-HPV DNA strands present in a saliva sample.

Among 46 patients identified with HPV-positive OPSCC, TTMV-HPV DNA in saliva samples was detected in 44 patients. The levels of TTMV-HPV in saliva were 18 times higher than in blood samples from the same patients, reported the study’s principal investigator, Jose P. Zevallos, MD, MPH, FACS, Chief, Head & Neck Oncologic Surgery, Washington University School of Medicine, St. Louis, MO, during a poster presentation at the meeting.

“The results of our study highlight the potential of accurately analyzing saliva to improve the early detection of HPV-associated OPSCC. If validated in larger studies, this test could lead to earlier diagnosis and treatment,” Dr Zevallos said.

Study Details

In the study, 46 patients with HPV-positive OPSCC with paired pretreatment plasma and saliva samples were identified from a banked biospecimen repository. Using the NavDx assay, TTMV was detectable for HPV-16 from 44 evaluable saliva samples and 43 evaluable plasma samples. There were 41 evaluable paired saliva and plasma samples, and HPV-16 status was positive in all. Of the 41 patients, 8 (19.5%) were current smokers and 18 (43.9%) were former smokers, with a median pack-years of 37.5. Of 41 evaluable patients, 38 (92.7%) were men, 36 (87.8%) had stage I-II cancer, and 5 (12.2%) had stage III-IV cancer.

HPV-18, -31, -33, and -35 were measured in the negative or indeterminate samples that were previously tested for HPV-16.

Compared with plasma, TTMV was significantly enriched in saliva (P <.0001), with median copy numbers of 14,139 copies/mL for saliva and 774.7 copies/mL for plasma. Plasma and saliva TTMV levels showed a significant positive correlation (r = .344; P = .028).

There was no difference in overall disease stage between sample types. In both sample types, there was a trend toward higher TTMV in patients with a history of smoking. When grouped by pack-years, plasma TTMV approached significance (P = .058) whereas high saliva TTMV was significantly associated with >10 pack-year history (P = .011).

References

  1. McQuillan G, Kruszon-Moran D, Markowitz LE, et al. Prevalence of HPV in adults aged 18-69: United States, 2011–2014. NCHS Data Brief. 2017;(280):1-8.
  2. Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.
  3. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235-3242.
  4. American Cancer Society. Key statistics for oral cavity and oropharyngeal cancers. Updated March 23, 2021. www.cancer.org/cancer/oral-cavity-and-oropharyngeal-cancer/about/key-statistics.html. Accessed June 23, 2021.
Related Items
Updated NCCN Guidelines Lower Age for Initial Colorectal Cancer Screening
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
Pembrolizumab Added to Best Supportive Care Extends Survival in Patients with Hepatocellular Carcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
New Treatment Strategies for Patients with Advanced Melanoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
The Future of Genetic Therapies and Value-Based Care in Oncology
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Community Provider Perspective: The Current and Future State of Cancer Care
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Biosimilars and the Road Ahead: Experts Discuss Opportunities and Challenges
William King
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in AVBCC Summit Highlights
Last modified: November 12, 2021